Evidence map›Paper›PMID 26821814›Full record

ArticleJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2016

Host response to Staphylococcus aureus cytotoxins in children with cystic fibrosis.

Ashley D Chadha, Isaac P Thomsen, Natalia Jimenez-Truque, Nicole R Soper, Lauren S Jones, Andrew G Sokolow, Victor J Torres, C Buddy Creech

Open access · bronzeAbstract read
In one paragraph

Article in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Molecular Characteristics and Pathogenicity ofInternational journal of molecular sciences · 2023
    Review
  2. Article
  3. Review
  4. Toxins · 2020
    Observational
  5. Review
  6. Article
  7. Microbiology spectrum · 2019
    Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Ashley D Chadha *Department of Pediatrics, Division of Allergy, Immunology, and Pulmonary Medicine, The Monroe Carell, Jr. Children's Hospital at Vanderbilt and the Vanderbilt University School of Medicine, Nashville, Tennessee.
Isaac P Thomsen *Department of Pediatrics, Division of Infectious Diseases, The Monroe Carell, Jr. Children's Hospital at Vanderbilt and the Vanderbilt University School of Medicine, Nashville, Tennessee.
Natalia Jimenez-TruqueDepartment of Pediatrics, Division of Infectious Diseases, The Monroe Carell, Jr. Children's Hospital at Vanderbilt and the Vanderbilt University School of Medicine, Nashville, Tennessee.
Nicole R SoperDepartment of Pediatrics, Division of Infectious Diseases, The Monroe Carell, Jr. Children's Hospital at Vanderbilt and the Vanderbilt University School of Medicine, Nashville, Tennessee.
Lauren S JonesDepartment of Pediatrics, Division of Infectious Diseases, The Monroe Carell, Jr. Children's Hospital at Vanderbilt and the Vanderbilt University School of Medicine, Nashville, Tennessee.
Andrew G SokolowDepartment of Pediatrics, Division of Allergy, Immunology, and Pulmonary Medicine, The Monroe Carell, Jr. Children's Hospital at Vanderbilt and the Vanderbilt University School of Medicine, Nashville, Tennessee.
Victor J TorresDepartment of Microbiology, New York University School of Medicine, New York, NY.
C Buddy CreechDepartment of Pediatrics, Division of Infectious Diseases, The Monroe Carell, Jr. Children's Hospital at Vanderbilt and the Vanderbilt University School of Medicine, Nashville, Tennessee.
Monroe Carell Jr. Children's Hospital · USNew York University · US

Funding

The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
Mechanistic Studies Of The Staphylococcus aureus LukAB CytotoxinR01AI099394 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Victor J. Torres · 2013 to 2026
$6.1M
Contribution of LukED to Staphylococcus aureus pathobiologyR01AI105129 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI TORRES, VICTOR J. · 2014 to 2023
$4.9M
Evaluating the Functional Antibody Response to Pediatric S. aureus InfectionsK23AI113150 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI THOMSEN, ISAAC P · 2014 to 2018
$887k
NCATS NIH HHS UL1 TR000445NIAID NIH HHS K23 AI113150NIAID NIH HHS R01 AI099394NIAID NIH HHS R01 AI105129
6 · The paper itself

Abstract

backgroundStaphylococcus aureus is one of the earliest bacterial pathogens to colonize the lungs of children with cystic fibrosis and is an important contributor to pulmonary exacerbations. The adaptive host response to S. aureus in cystic fibrosis remains inadequately defined and has important implications for pathogenesis and potential interventions. The objectives of this study were to determine the functional antibody response to select staphylococcal exotoxins (LukAB, alpha-hemolysin, and PVL) in children with cystic fibrosis and to evaluate the relationship of this response with pulmonary exacerbations.

methodsFifty children with cystic fibrosis were enrolled and followed prospectively for 12months. Clinical characteristics and serologic profiles were assessed at routine visits and during pulmonary exacerbations, and functional antibody assessments were performed to measure neutralization of LukAB-mediated cytotoxicity.

resultsFor each antigen, geometric mean titers were significantly higher if S. aureus was detected at the time of exacerbation. For LukAB, geometric mean titers were significantly higher at exacerbation follow-up compared to titers during the exacerbation, consistent with expression during human disease, and the humoral response capably neutralized LukAB-mediated cytotoxicity. Moreover, the presence of a positive S. aureus culture during a pulmonary exacerbation was associated with 31-fold higher odds of having a LukA titer ≥1:160, suggesting potential diagnostic capability of this assay.

conclusionsThe leukotoxin LukAB is expressed by S. aureus and recognized by the human adaptive immune response in the setting of pulmonary infection in cystic fibrosis. Anti-LukAB antibodies were not only predictive of positive staphylococcal culture during exacerbation, but also functional in the neutralization of this toxin.

Indexed as

Cystic FibrosisStaphylococcal InfectionsStaphylococcus aureusAdaptive ImmunityAdolescentAntibody FormationBacterial ProteinsChildChild, PreschoolCytotoxinsFemaleHumansLeukocidinsLung DiseasesMaleProspective StudiesBacterial ProteinsCytotoxinsleukocidin AB, Staphylococcus aureusLeukocidinsCystic fibrosisExotoxinsLukABSerologyStaphylococcus aureus

Identifiers

PMID26821814
PMCPMC4959994
OpenAlexW2252041879

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.